Pan-cancer analysis identifies KANSL2 as a cell-cycle–associated regulator of tumor progression and immunity in liver hepatocellular carcinoma Authors: Nanbin Liu, Kun Li, Junqiao Feng, Shan Wang, Ji Li, Wenbin Yang, Senyang Li, Keping Feng Published: 2026 ABSTRACT KANSL2, a core component of the NSL histone acetyltransferase complex, has been implicated in tumorigenesis. However, its pan-cancer relevance and functional role in liver hepatocellular carcinoma (LIHC) remain unclear. Multi-omics data from TCGA, GEO, and HPA were integrated to systematically evaluate KANSL2 expression, clinical significance, genomic alterations, and immune associations across cancers. Functional enrichment, immune infiltration analyses, and single-cell transcriptomics were performed. In vitro assays were conducted to validate the biological effects of KANSL2 in LIHC cells. KANSL2 is broadly upregulated across cancers and exhibits strong diagnostic performance. Elevated KANSL2 expression correlates with unfavorable prognosis, particularly in LIHC. Mechanistically, KANSL2 and its co-expressed genes are enriched in cell-cycle progression. KANSL2 expression is also closely associated with immune infiltration and immunoregulatory signaling within the tumor microenvironment, with single-cell data indicating preferential expression in proliferative T-cell subsets. Functional experiments demonstrate that KANSL2 silencing suppresses proliferation, migration, and invasion, and induces G2/M phase arrest in LIHC cells. Notably, its effects on apoptosis are limited, suggesting that KANSL2 primarily drives tumor progression through cell-cycle-dependent mechanisms. This study identifies KANSL2 as a key regulator of tumor progression and immune remodeling in LIHC. By promoting malignancy predominantly via cell-cycle control, KANSL2 represents a promising biomarker for diagnosis and prognosis, and a potential therapeutic target.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s10238-026-02264-7. Introduction The global cancer burden continues to escalate, with projections estimating approximately 28 million new cases annually by 2040 [1]. Despite substantial progress in early detection approaches, malignancies remain a leading reason of death and pose a significant public health challenge worldwide. Primary liver cancer has shown a steadily rising incidence across different populations [2–4]. Highlighting the urgent demand for more effective prevention and treatment strategies [5]. LIHC is the most common histological subtype of primary liver cancer, accounting for nearly 85% of cases. Its development is closely linked to chronic liver conditions, including hepatitis B virus infection and liver cirrhosis [6]. Due to its asymptomatic nature in early stages and the lack of reliable biomarkers for early detection, LIHC is often diagnosed at advanced stages [7]. Although various treatment strategies—such as surgical resection, locoregional interventions, targeted therapies, and immunotherapy—have been introduced, outcomes for patients with advanced disease remain unsatisfactory [8]. Therefore, identifying reliable biomarkers and uncovering novel molecular mechanisms are essential for improving early diagnosis and therapeutic strategies in LIHC. KANSL2 (KAT8-regulatory NSL complex subunit 2), also referred to as NSL2 or C12orf41, is a protein-coding gene located on chromosome 12 [9]. Data from the Genecards database [10] indicate that KANSL2 and its homologs are highly conserved across multiple species, including mouse, Anolis carolinensis, chicken, zebrafish, and Xenopus laevis. As a component of the nonspecific lethal (NSL) complex, KANSL2 is distributed across several cellular compartments, such as the cytoplasm, nucleoplasm, and actin cytoskeleton [11]. Functionally, it acts as a non-catalytic subunit of the NSL histone acetyltransferase complex and participates in the regulation of histone H4 acetylation at lysine residues (H4K5 and H4K8), thereby contributing to transcriptional activation and potentially influencing cancer-related biological processes [12]. In addition to its physiological functions, KANSL2 has been associated with multiple human disorders, including autosomal dominant intellectual developmental disorder (MRD52) [13], chondrodysplasia accompanied by congenital anomalies [14], and late-onset Alzheimer’s disease [15]. Increasing evidence also implicates KANSL2 in cancer biology, where it may function as both a risk factor and a prognostic indicator in various malignancies, such as pancreatic adenocarcinoma (PAAD), triple-negative breast cancer (BRCA), glioblastoma (GBM), and multiple myeloma (MM) [16–19]. However, despite these findings, the role of KANSL2 in LIHC remains poorly understood, and its potential mechanisms in tumor progression have not been fully elucidated. Advances in high-throughput sequencing technologies and bioinformatics have enabled integrative multi-omics analyses to systematically characterize cancer-related genes and their clinical implications [20]. In this study, we initially performed a pan-cancer screening analysis to evaluate the expression patterns and clinical relevance of KANSL2 across multiple tumor types, aiming to identify cancer types in which KANSL2 may play a prominent role. Based on these findings, we focused in LIHC for in-depth investigation. We systematically analyzed the association of KANSL2 with clinical characteristics, prognostic value, and potential biological functions in LIHC using integrated datasets from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Human Protein Atlas (HPA). Functional enrichment and pathway analyses were conducted to explore the underlying molecular mechanisms, with particular emphasis on cell cycle–related processes. In addition, in vitro experiments were performed to validate the biological role of KANSL2 in LIHC cells. Collectively, our findings highlight the potential involvement of KANSL2 in LIHC progression and suggest that it may serve as a promising biomarker and therapeutic target. Materials and methods Data acquisition and preprocessing Transcriptomic data and corresponding clinical information were obtained from TCGA and GEO databases. When normal tissue samples in TCGA were insufficient, additional data from the Genotype-Tissue Expression (GTEx) project were incorporated. Protein expression data were retrieved from HPA. All datasets were standardized and normalized prior to downstream analyses [21–23]. Bioinformatics analysis Pan-cancer analyses were initially performed to evaluate the expression patterns of KANSL2 across multiple tumor types. Based on these results, LIHC was selected for further investigation. Differential expression analysis, survival analysis, and clinicopathological correlation were conducted to assess the role of KANSL2 in LIHC. To explore the underlying biological mechanisms, co-expression analysis and functional enrichment analyses, including GO, KEGG, and GSEA, were performed. The tumor immune microenvironment was characterized using established computational approaches. Additional analyses, including genomic alterations, single-cell transcriptomics, and drug response prediction, were conducted to provide complementary insights [24–43]. Cell culture and transfection LIHC cell lines were cultured under standard conditions. Cells were transfected with siRNAs targeting KANSL2 or a negative control using a lipid-based transfection reagent. Western blot analysis Protein expression levels were determined by Western blot using standard experimental procedures. Functional assays CCK8 is used to assess cell proliferation. Cell-cycle distribution and apoptosis were analyzed by flow cytometry. Transwell assays were conducted to evaluate cell migration and invasion capabilities. Statistical analysis All statistical analyses were performed using R software and GraphPad Prism. Appropriate statistical tests were applied for group comparisons. Survival analyses were conducted using Kaplan–Meier methods and Cox proportional hazards models. A two-tailed P value < 0.05 was considered statistically significant. Results Distribution of KANSL2 in normal human tissues and organs To provide a baseline for interpreting its role in cancer, the expression pattern of KANSL2 in normal human tissues was evaluated using HPA and GTEx datasets. The results showed that KANSL2 is broadly expressed across multiple tissue types, with relatively higher expression observed in several metabolically active and immune-related tissues (Fig. S1A–D). At the protein level, KANSL2 exhibited widespread distribution across major organ systems, while maintaining certain tissue-specific expression patterns, particularly in testicular and muscle tissues (Fig. S1E–F). In addition, expression was detectable in various immune cell populations, suggesting a potential link to immune-related processes. Single-cell transcriptomic data further supported the ubiquitous expression of KANSL2, with relatively higher levels observed in specific cell populations such as lymphocytes and glial cells (Fig. S1G). Subcellular localization analysis indicated that KANSL2 is predominantly localized in the nucleoplasm and cytosol (Fig. S1H–J), consistent with its reported role in transcriptional regulation. Collectively, these findings indicate that KANSL2 is widely expressed in normal tissues, providing a reference for its dysregulation in cancer and supporting its potential involvement in fundamental cellular processes, supporting its potential involvement in fundamental cellular processes relevant to tumor progression. KANSL2 Is upregulated across multiple cancer types To identify cancer types in which KANSL2 may play a potential role, a pan-cancer expression analysis was performed using TCGA datasets. The results showed that KANSL2 expression was significantly upregulated in multiple tumor types compared with normal tissues, while downregulation was observed in a limited number of cancers (Fig. 1A–B).Fig. 1Pan-cancer and LIHC expression profiling of KANSL2. (A) Differential expression of KANSL2 between tumor and normal tissues in unpaired samples. (B) Paired comparison of KANSL2 expression between tumor and adjacent normal tissues. (C) Expression landscape of KANSL2 across human cancer cell lines. (D) Expression of KANSL2 in LIHC cell lines. (E-L) Validation of KANSL2 expression using independent GEO datasets (GSE42568, GSE44861, GSE29721, GSE39791, GSE45267, GSE112790, GSE121248, GSE29272). Tumor and normal samples were compared using t-test. (M) IHC images from HPA showing KANSL2 protein expression in tumor and corresponding normal tissues. (N-S) Spatial transcriptomic maps showing the distribution and regional heterogeneity of KANSL2 expression in tumor and adjacent tissues across multiple cancer types. Color intensity represents normalized KANSL2 expression levels. Data were obtained from TCGA, GEO and HPA. *P < 0.05, **P < 0.01, ***P < 0.001 Pan-cancer and LIHC expression profiling of KANSL2. (A) Differential expression of KANSL2 between tumor and normal tissues in unpaired samples. (B) Paired comparison of KANSL2 expression between tumor and adjacent normal tissues. (C) Expression landscape of KANSL2 across human cancer cell lines. (D) Expression of KANSL2 in LIHC cell lines. (E-L) Validation of KANSL2 expression using independent GEO datasets (GSE42568, GSE44861, GSE29721, GSE39791, GSE45267, GSE112790, GSE121248, GSE29272). Tumor and normal samples were compared using t-test. (M) IHC images from HPA showing KANSL2 protein expression in tumor and corresponding normal tissues. (N-S) Spatial transcriptomic maps showing the distribution and regional heterogeneity of KANSL2 expression in tumor and adjacent tissues across multiple cancer types. Color intensity represents normalized KANSL2 expression levels. Data were obtained from TCGA, GEO and HPA. *P < 0.05, **P < 0.01, ***P < 0.001 Further analysis of cancer cell lines and independent GEO datasets consistently supported the elevated expression of KANSL2 in several malignancies (Fig. 1C–L). Notably, KANSL2 was markedly upregulated in LIHC, suggesting its potential relevance in this cancer type. At the protein level, immunohistochemical data from the HPA database confirmed increased KANSL2 expression in various tumor tissues, including LIHC (Fig. 1M). In addition, spatial transcriptomic analysis demonstrated higher expression of KANSL2 in tumor regions compared with adjacent normal tissues (Fig. 1N–S). Collectively, these findings indicate that KANSL2 is frequently upregulated across cancers and highlight LIHC as a representative tumor type for further investigation. In addition, pan-cancer diagnostic and genomic alteration analyses further supported the potential clinical relevance of KANSL2 across multiple tumor types (Fig. S2–S3). Prognostic value of KANSL2 in LIHC We first performed pan-cancer survival analyses, which suggested that elevated KANSL2 expression was associated with unfavorable prognosis in several tumor types (Fig. 2A–F). Notably, LIHC showed a consistent and significant association, prompting further focused investigation.Fig. 2Prognostic significance of KANSL2 in LIHC. (A-C) Forest plots showing the results of OS, DSS, and PFI based on KANSL2 expression. (D-F) Heatmaps summarizing the prognostic associations of KANSL2 across multiple cancer types for OS, DSS, and PFI. (G-I) K-M survival curves for OS, DSS, and PFI in LIHC patients stratified into high- and low-KANSL2 expression groups (J) Distribution of survival status and risk scores derived from KANSL2 expression in LIHC. (K) Prognostic nomogram integrating KANSL2 expression and clinical variables for predicting survival probability in LIHC patients. (L) Calibration curves evaluating the predictive accuracy of the nomogram. Data were obtained from TCGA. *P < 0.05 Prognostic significance of KANSL2 in LIHC. (A-C) Forest plots showing the results of OS, DSS, and PFI based on KANSL2 expression. (D-F) Heatmaps summarizing the prognostic associations of KANSL2 across multiple cancer types for OS, DSS, and PFI. (G-I) K-M survival curves for OS, DSS, and PFI in LIHC patients stratified into high- and low-KANSL2 expression groups (J) Distribution of survival status and risk scores derived from KANSL2 expression in LIHC. (K) Prognostic nomogram integrating KANSL2 expression and clinical variables for predicting survival probability in LIHC patients. (L) Calibration curves evaluating the predictive accuracy of the nomogram. Data were obtained from TCGA. *P < 0.05 In LIHC, Kaplan–Meier survival analyses demonstrated that patients with high KANSL2 expression had significantly poorer overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) (Fig. 2G–I). Subgroup analyses further confirmed the robustness of this association across multiple clinical strata, including tumor stage and metastasis status (Fig. S4A–J). Univariate Cox regression analysis identified tumor stage, metastasis status, tumor status, and KANSL2 expression as significant prognostic factors. Multivariate analysis demonstrated that KANSL2 expression remained an independent predictor of patient outcomes (P = 0.033), along with tumor status (P = 0.010) (Table 1).Table 1Cox regression analysis in LIHCCharacteristicsTotal(N)Univariate analysisMultivariate analysisHazard ratio (95% CI)P valueHazard ratio (95% CI)P valuePathologic stage349Stage I173ReferenceReferenceStage II861.417 (0.868—2.312)0.1641.383 (0.828—2.309)0.215Stage III852.734 (1.792—4.172) < 0.0012.429 (1.549—3.807) < 0.001Stage IV55.597 (1.726—18.148)0.0043.211 (0.760—13.564)0.112Tumor status354Tumor free202ReferenceReferenceWith tumor1522.317 (1.590—3.376) < 0.0011.712 (1.139—2.573)0.010Gender373Female121ReferenceMale2520.793 (0.557—1.130)0.200Race361Asian159ReferenceBlack or African American&White2021.341 (0.926—1.942)0.121Age373 < = 60177Reference > 601961.205 (0.850—1.708)0.295BMI336 < = 25177Reference > 251590.798 (0.550—1.158)0.235Residual tumor344R0326ReferenceR1&R2181.604 (0.812—3.169)0.174Histologic grade368G155ReferenceG21781.162 (0.686—1.969)0.576G31231.185 (0.683—2.057)0.545G4121.681 (0.621—4.549)0.307AFP(ng/ml)279 < = 400215Reference > 400641.075 (0.658—1.759)0.772Albumin(g/dl)299 < 3.569Reference > = 3.52300.897 (0.549—1.464)0.662Prothrombin time296 < = 4207Reference > 4891.335 (0.881—2.023)0.174Child–Pugh grade240A218ReferenceB&C221.643 (0.811—3.330)0.168Fibrosis ishak score214075Reference1/2310.936 (0.437—2.002)0.8643/4280.699 (0.288—1.695)0.428590.764 (0.181—3.228)0.7146710.734 (0.401—1.345)0.317Vascular invasion317No208ReferenceYes1091.344 (0.887—2.035)0.163Adjacent hepatic tissue inflammation236None118ReferenceMild1011.204 (0.723—2.007)0.476Severe171.144 (0.447—2.930)0.779KANSL2373Low187ReferenceReferenceHigh1861.646 (1.161—2.333)0.0051.532 (1.034—2.269)0.033 Table 1Cox regression analysis in LIHCCharacteristicsTotal(N)Univariate analysisMultivariate analysisHazard ratio (95% CI)P valueHazard ratio (95% CI)P valuePathologic stage349Stage I173ReferenceReferenceStage II861.417 (0.868—2.312)0.1641.383 (0.828—2.309)0.215Stage III852.734 (1.792—4.172) < 0.0012.429 (1.549—3.807) < 0.001Stage IV55.597 (1.726—18.148)0.0043.211 (0.760—13.564)0.112Tumor status354Tumor free202ReferenceReferenceWith tumor1522.317 (1.590—3.376) < 0.0011.712 (1.139—2.573)0.010Gender373Female121ReferenceMale2520.793 (0.557—1.130)0.200Race361Asian159ReferenceBlack or African American&White2021.341 (0.926—1.942)0.121Age373 < = 60177Reference > 601961.205 (0.850—1.708)0.295BMI336 < = 25177Reference > 251590.798 (0.550—1.158)0.235Residual tumor344R0326ReferenceR1&R2181.604 (0.812—3.169)0.174Histologic grade368G155ReferenceG21781.162 (0.686—1.969)0.576G31231.185 (0.683—2.057)0.545G4121.681 (0.621—4.549)0.307AFP(ng/ml)279 < = 400215Reference > 400641.075 (0.658—1.759)0.772Albumin(g/dl)299 < 3.569Reference > = 3.52300.897 (0.549—1.464)0.662Prothrombin time296 < = 4207Reference > 4891.335 (0.881—2.023)0.174Child–Pugh grade240A218ReferenceB&C221.643 (0.811—3.330)0.168Fibrosis ishak score214075Reference1/2310.936 (0.437—2.002)0.8643/4280.699 (0.288—1.695)0.428590.764 (0.181—3.228)0.7146710.734 (0.401—1.345)0.317Vascular invasion317No208ReferenceYes1091.344 (0.887—2.035)0.163Adjacent hepatic tissue inflammation236None118ReferenceMild1011.204 (0.723—2.007)0.476Severe171.144 (0.447—2.930)0.779KANSL2373Low187ReferenceReferenceHigh1861.646 (1.161—2.333)0.0051.532 (1.034—2.269)0.033 Cox regression analysis in LIHC Consistently, Risk Factor Chart revealed that patients with high KANSL2 expression exhibited significantly worse survival outcomes (Fig. 2J). A prognostic nomogram incorporating KANSL2 expression was further constructed (Fig. 2K), and calibration curves indicated good agreement (Fig. 2L). Taken together, these results demonstrate that KANSL2 is a robust and independent prognostic biomarker in LIHC. Association between KANSL2 and clinicopathological features in LIHC Given the significant prognostic impact of KANSL2 in LIHC, we next investigated its association with clinicopathological characteristics. Elevated KANSL2 expression was significantly associated with advanced tumor stage, higher histological grade, increased tumor burden, and elevated AFP levels (Fig. 3A).Fig. 3Clinical relevance of KANSL2 in LIHC. (A) Multivariate logistic regression analysis assessing the association between KANSL2 expression and clinicopathological characteristics. (B-I) Violin plots showing the distribution of KANSL2 expression across different clinical subgroups. Patients were stratified based on clinicopathological characteristics, including pathological T stage (B), pathological stage (C), tumor status (D), gender (E), age (F), BMI (G), histological grade (H), and AFP level (I). For all comparisons, expression levels of KANSL2 were derived from TCGA RNA-seq data (TPM values, log2-transformed). Statistical significance between two groups was evaluated using t-test. *P < 0.05, **P < 0.01, ***P < 0.001 Clinical relevance of KANSL2 in LIHC. (A) Multivariate logistic regression analysis assessing the association between KANSL2 expression and clinicopathological characteristics. (B-I) Violin plots showing the distribution of KANSL2 expression across different clinical subgroups. Patients were stratified based on clinicopathological characteristics, including pathological T stage (B), pathological stage (C), tumor status (D), gender (E), age (F), BMI (G), histological grade (H), and AFP level (I). For all comparisons, expression levels of KANSL2 were derived from TCGA RNA-seq data (TPM values, log2-transformed). Statistical significance between two groups was evaluated using t-test. *P < 0.05, **P < 0.01, ***P < 0.001 Further subgroup analyses demonstrated that high KANSL2 expression was closely correlated with aggressive disease features, such as, tumor progression, vascular invasion, and metastasis status (Fig. 3B–I). These findings suggest that KANSL2 expression is associated with more aggressive tumor phenotypes in LIHC, which may partially explain its adverse prognostic impact. Co-expression Network, PPI analysis and functional enrichment of KANSL2 in LIHC We first constructed a co-expression network and identified the top 30 genes positively correlated with KANSL2 (Fig. 4A). These genes exhibited consistent expression patterns and strong internal correlations across samples (Fig. 4B–D), and many were also significantly associated with patient prognosis (Fig. 4E).Fig. 4Co-expression network of KANSL2 in LIHC. (A) Heatmap showing the top genes co-expressed with KANSL2. (B) Pan-cancer correlation landscape illustrating the association between KANSL2 expression and co-expressed genes in pan-cancer. Correlation coefficients were calculated using Spearman’s correlation analysis. (C-D) Circular correlation plots depicting the co-expression relationships between KANSL2 and representative genes in LIHC. Edge thickness represents correlation strength, and color indicates positive or negative correlations. (E) K-M survival analyses of representative KANSL2 co-expressed genes in LIHC. (F) Functional pathway enrichment analysis of KANSL2-associated genes. Pathway activity scores were categorized as activation or inhibition based on GSVA-derived enrichment scores. Red indicates activation, and blue indicates inhibition. Data were obtained from TCGA-LIHC cohort and pan-cancer datasets. Statistical significance was assessed using Spearman correlation or log-rank test where appropriate Co-expression network of KANSL2 in LIHC. (A) Heatmap showing the top genes co-expressed with KANSL2. (B) Pan-cancer correlation landscape illustrating the association between KANSL2 expression and co-expressed genes in pan-cancer. Correlation coefficients were calculated using Spearman’s correlation analysis. (C-D) Circular correlation plots depicting the co-expression relationships between KANSL2 and representative genes in LIHC. Edge thickness represents correlation strength, and color indicates positive or negative correlations. (E) K-M survival analyses of representative KANSL2 co-expressed genes in LIHC. (F) Functional pathway enrichment analysis of KANSL2-associated genes. Pathway activity scores were categorized as activation or inhibition based on GSVA-derived enrichment scores. Red indicates activation, and blue indicates inhibition. Data were obtained from TCGA-LIHC cohort and pan-cancer datasets. Statistical significance was assessed using Spearman correlation or log-rank test where appropriate Functional enrichment analysis of KANSL2-associated genes suggested involvement in multiple cancer-related biological processes, with a prominent enrichment in cell cycle regulation, along with apoptosis and signaling-related pathways (Fig. 4F). The PPI network revealed strong interactions between KANSL2 and multiple hub genes (Fig. 5A-B), which also showed consistent co-expression patterns across cancers (Fig. 5C). Functional enrichment indicated involvement in cell cycle regulation, apoptosis, EMT, and signaling pathways (Fig. 5D). Several hub genes, including MCRS1, KANSL3, HCFC1, and MSL3, were significantly associated with LIHC prognosis (Fig. 5E).Fig. 5PPI network and functional analysis of KANSL2-associated genes. (A) PPI network of KANSL2-associated genes constructed using the STRING database. (B) Circular correlation plot showing the co-expression relationships among hub genes. Correlation coefficients were calculated using Spearman’s correlation analysis, and edge thickness represents the strength of correlation. (C) Pan-cancer co-expression heatmap illustrating the correlation between KANSL2 and hub genes across multiple cancer types. (D) Pathway activity analysis of hub genes across cancers. Based on gene set variation analysis (GSVA) scores. (E) K-M survival curves showing the prognostic significance of representative hub genes in LIHC. Data were obtained from TCGA and STRING databases PPI network and functional analysis of KANSL2-associated genes. (A) PPI network of KANSL2-associated genes constructed using the STRING database. (B) Circular correlation plot showing the co-expression relationships among hub genes. Correlation coefficients were calculated using Spearman’s correlation analysis, and edge thickness represents the strength of correlation. (C) Pan-cancer co-expression heatmap illustrating the correlation between KANSL2 and hub genes across multiple cancer types. (D) Pathway activity analysis of hub genes across cancers. Based on gene set variation analysis (GSVA) scores. (E) K-M survival curves showing the prognostic significance of representative hub genes in LIHC. Data were obtained from TCGA and STRING databases In addition, differential expression analysis identified 5,608 DEGs (Fig. 6A–B). Functional enrichment analyses indicated that upregulated genes were mainly involved in metabolic processes, whereas downregulated genes were enriched in cell division-related functions (Fig. 6C). Consistently, GSEA revealed significant enrichment of cell cycle–related pathways, including mitotic checkpoint regulation and cell division, in the KANSL2-high group, while extracellular matrix organization and differentiation-related pathways were suppressed (Fig. 6D–M).Fig. 6Functional enrichment analysis of KANSL2-associated genes in LIHC. (A) Volcano plot showing DEGs between high- and low-KANSL2 expression groups. (B) Heatmap displaying the expression patterns of DEGs across LIHC samples. (C) GO and KEGG enrichment analyses of DEGs. The size of the dots represents gene counts, and color indicates the adjusted P value. (D-M) GSEA illustrating significantly enriched pathways associated with KANSL2 expression. The left panels show enrichment plots with NES and FDR. The right panels display Spearman correlation analyses between KANSL2 expression and representative pathway-related genes. Each dot represents an individual sample. Data were obtained from the TCGA-LIHC cohort Functional enrichment analysis of KANSL2-associated genes in LIHC. (A) Volcano plot showing DEGs between high- and low-KANSL2 expression groups. (B) Heatmap displaying the expression patterns of DEGs across LIHC samples. (C) GO and KEGG enrichment analyses of DEGs. The size of the dots represents gene counts, and color indicates the adjusted P value. (D-M) GSEA illustrating significantly enriched pathways associated with KANSL2 expression. The left panels show enrichment plots with NES and FDR. The right panels display Spearman correlation analyses between KANSL2 expression and representative pathway-related genes. Each dot represents an individual sample. Data were obtained from the TCGA-LIHC cohort Collectively, these findings suggest that KANSL2 may promote LIHC progression through coordinated regulation of cell cycle–associated gene networks. In addition to the core mechanistic findings, we performed a series of complementary analyses to further explore the potential roles of KANSL2. These included immune microenvironment characterization, single-cell expression profiling, drug sensitivity prediction, molecular docking, and epigenetic association analyses. The results suggested that KANSL2 may be involved in immune regulation, therapeutic response, and multiple regulatory pathways across cancers. Detailed results are provided in the Supplementary Materials (Fig. S5-S8). Functional validation of KANSL2 in LIHC cells To validate the functional role of KANSL2 in LIHC, KANSL2 expression was silenced in Hep3B and MHCC97H cells, resulting in a significant reduction at the protein level (Fig. 7A-B).Fig. 7Functional validation of KANSL2 in LIHC cells. (A-B) Validation of KANSL2 knockdown efficiency in LIHC cell lines (e.g.,Hep3B and MHCC97H ) by Western blot analysis following transfection with KANSL2-specific siRNA or control siRNA. (C-D) Cell proliferation assays showing reduced proliferation after KANSL2 silencing, as measured by CCK-8 assay. (E–F) Cell cycle analysis by flow cytometry demonstrating G2/M phase arrest in KANSL2-silenced cells. (G-H) Transwell migration and invasion assays showing decreased migratory and invasive abilities after KANSL2 knockdown. (I-J) Flow cytometry analysis of apoptosis in LIHC cells following KANSL2 knockdown. Data are presented as mean ± SD. Statistical significance was evaluated using t-test, *P < 0.05, **P < 0.01, ***P < 0.001 Functional validation of KANSL2 in LIHC cells. (A-B) Validation of KANSL2 knockdown efficiency in LIHC cell lines (e.g.,Hep3B and MHCC97H ) by Western blot analysis following transfection with KANSL2-specific siRNA or control siRNA. (C-D) Cell proliferation assays showing reduced proliferation after KANSL2 silencing, as measured by CCK-8 assay. (E–F) Cell cycle analysis by flow cytometry demonstrating G2/M phase arrest in KANSL2-silenced cells. (G-H) Transwell migration and invasion assays showing decreased migratory and invasive abilities after KANSL2 knockdown. (I-J) Flow cytometry analysis of apoptosis in LIHC cells following KANSL2 knockdown. Data are presented as mean ± SD. Statistical significance was evaluated using t-test, *P < 0.05, **P < 0.01, ***P < 0.001 CCK-8 assays demonstrated that KANSL2 silencing significantly inhibited cell viability at 72 h (Fig. 7C-D), indicating impaired proliferative capacity. Consistently, flow cytometry analysis revealed that KANSL2 knockdown led to a marked accumulation of cells in the G2/M phase (Fig. 7E-F), indicating cell-cycle arrest. Furthermore, Transwell assays showed that KANSL2 knockdown markedly reduced the migratory and invasive abilities of LIHC cells (Fig. 7G-H). Apoptosis analysis showed only minor and inconsistent changes following KANSL2 silencing (Fig. 7I-J), suggesting that apoptosis is not a primary functional outcome of KANSL2 in LIHC cells. Collectively, these results indicate that KANSL2 promotes LIHC cell proliferation and metastasis primarily through regulation of cell-cycle progression. Discussion In this study, we conducted an integrative investigation of KANSL2 with an emphasis on its role in LIHC. Although pan-cancer datasets were incorporated to provide a broader landscape of expression patterns and clinical relevance, the primary focus of our analysis was its functional significance in LIHC. Our results show that KANSL2 is significantly upregulated in LIHC and correlates with unfavorable prognosis and more aggressive tumor characteristics. Mechanistic insights derived from both computational approaches and in vitro assays consistently support a role for KANSL2 in promoting tumor progression, mainly through modulation of cell-cycle processes. Additional analyses revealed potential links to immune-related features and other regulatory pathways; however, these associations remain largely correlative. Collectively, our findings suggest that KANSL2 functions as a biologically relevant regulator in LIHC, particularly in the context of tumor cell proliferation. KANSL2 serves as an essential component of the NSL (non-specific lethal) complex, a conserved chromatin-regulating complex that modulates transcription via histone acetylation, especially through MOF/KAT8-dependent H4K16 acetylation [44]. This epigenetic role provides a plausible explanation for the widespread transcriptional alterations associated with KANSL2 in our analysis. Accumulating evidence indicates that NSL complex members participate in multiple biological processes, including cellular development, metabolic regulation, and oncogenesis [45]. For example, KANSL3 has been linked to mitotic control and mitochondrial activity [46], whereas MCRS1 contributes to transcriptional regulation and tumor recurrence [47]. Within this framework, our study expands the functional relevance of the NSL complex by identifying KANSL2 as a clinically meaningful factor in LIHC. Genetic alterations in KANSL2 were found to be relatively uncommon, suggesting that its dysregulation in LIHC is unlikely to be mutation-driven. Instead, associations with copy-number variation, along with correlations involving TMB and MSI, imply that KANSL2 expression may be influenced by broader transcriptional or epigenetic regulatory programs. Considering that TMB and MSI are commonly linked to immunotherapy responsiveness [48], these relationships may reflect underlying tumor characteristics rather than a direct mechanistic role of KANSL2. Accordingly, these findings should be interpreted cautiously and require further experimental validation. One of the most prominent findings of this study is the strong association between KANSL2 and cell-cycle regulation in LIHC. Multiple analytical approaches, including differential expression, co-expression, and PPI network analyses, consistently demonstrated enrichment of KANSL2-related genes in pathways involved in mitosis, chromosome segregation, and the G2/M transition. Notably, these computational results were corroborated by experimental data showing that KANSL2 knockdown induces significant G2/M phase arrest and reduces proliferative capacity in LIHC cells. Given the central role of cell-cycle dysregulation in hepatocarcinogenesis [49], these findings indicate that KANSL2 primarily acts as a regulator of cell-cycle progression. This convergence of computational and experimental evidence represents the strongest mechanistic support in our study and suggests a potential targetable vulnerability. Beyond its role in proliferation, KANSL2 may also influence tumor progression by modulating invasive behavior. Enrichment analyses pointed to potential involvement in pathways associated with cell motility, and functional assays confirmed that silencing KANSL2 suppresses migration and invasion in LIHC cells. Nevertheless, these effects are likely secondary to its primary function in controlling cell-cycle dynamics. We further identified associations between KANSL2 expression and characteristics of the tumor immune microenvironment. These included correlations with immune cell, immune checkpoint molecules, and chemokine-related signaling pathways across multiple cancer types. In LIHC, KANSL2 expression showed positive correlations with CD274 and CTLA4. Importantly, these findings are derived from bioinformatic analyses and therefore represent correlative relationships rather than direct mechanistic evidence. Further experimental work is necessary to determine whether KANSL2 actively regulates immune-related processes. Interestingly, KANSL2 depletion resulted in decreased apoptotic rates despite significantly suppressing proliferation. This observation suggests that the dominant function of KANSL2 in LIHC is to regulate cell-cycle progression rather than directly control apoptosis. The differences in baseline apoptotic levels between Hep3B and MHCC97H cells likely reflect intrinsic biological heterogeneity between HCC cell lines, including genetic background and proliferation states, which is commonly observed in in vitro cancer models and does not affect the overall directional interpretation of the results. One possible explanation is that KANSL2 inhibition induces a cytostatic condition characterized by cell-cycle arrest, thereby limiting proliferation without immediately triggering apoptosis. These results further reinforce the central role of cell-cycle regulation in KANSL2-mediated tumor biology. From a translational standpoint, our analyses indicate that KANSL2 expression may be linked to therapeutic response. Associations with predicted drug sensitivity, as well as correlations with ferroptosis-related genes and m6A regulators, were observed. However, these findings are based on computational predictions and should be regarded as preliminary. Additional experimental studies are required to determine whether KANSL2 directly influences these regulatory pathways or treatment responses. Several limitations should be considered. Although our integrative analyses combined with in vitro validation support a role for KANSL2 in regulating the cell cycle, the detailed downstream molecular mechanisms remain to be clarified. Furthermore, conclusions regarding immune regulation, ferroptosis, epigenetic modification, and drug response are largely based on correlative data and require further validation. Finally, in vivo experiments and larger clinical cohorts are needed to confirm the clinical applicability of our findings. In conclusion, this study provides a comprehensive evaluation of KANSL2 and establishes it as a functionally important regulator in LIHC. Our results emphasize its central role in driving tumor progression through cell-cycle regulation, supported by both computational and experimental evidence. While additional associations with immune and other regulatory pathways were observed, these require further investigation. Overall, KANSL2 represents a promising candidate for prognostic assessment and potential therapeutic targeting in LIHC. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file 1Supplementary file 2 Supplementary file 1 Supplementary file 2